Catalyst Wire Dossier Catalyst Wire Dossier

MAGE-3.A1 peptide

MAGE-3.A1 peptide · Ludwig Institute for Cancer Research
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MAGE-3.A1 peptide, covering 2021-07-21 to 2021-07-21. Get the full timeline:

Most recent: Clinical Trial Update: Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma [Phase 1, Phase 2]

See pricing